Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial - 05/08/11
, Joanne Micale Foody, MD b, Julie M. Miller, MD c, Carolyn Apperson-Hansen, MStat d, E. Magnus Ohman, MD e, Judith S. Hochman, MD f, Sharon L. Karnash, BS e, Robert M. Califf, MD e, Eric J. Topol, MD g, David J. Moliterno, MD aRésumé |
Background |
The role of hormone replacement therapy (HRT) in the prevention of cardiovascular disease has been controversial. In large observational studies, HRT appears to lower cardiovascular disease risk. However, prospective randomized trials do not substantiate this.
Methods |
We sought to characterize the use of HRT in women presenting with acute myocardial infarction and to investigate an association between HRT and inhospital or 30-day outcomes among women enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries III (GUSTO-III) trial. Of the 15 059 patients in GUSTO-III, 4124 were women. Menopausal status, HRT use, and clinical outcomes data were prospectively collected.
Results |
Postmenopausal women taking HRT were significantly younger than those not taking HRT, and US women were more likely to be prescribed HRT than non-US women. While unadjusted 30-day mortality was substantially lower in HRT patients (6.1% vs 12.7%, P < .001), HRT use was not independently predictive of mortality after correcting for baseline differences (χ2 = 0.15, P = .70).
Conclusion |
Hormone replacement therapy appears to have no early mortality benefit in women sustaining acute myocardial infarction. These findings further challenge the role of HRT in cardiovascular medicine.
Le texte complet de cet article est disponible en PDF.Plan
Vol 160 - N° 4
P. 678-684 - octobre 2010 Retour au numéro
Article précédent
- Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial
- Mustafa Toma, Yuling Fu, Justin A. Ezekowitz, Finlay A. McAlister, Cynthia M. Westerhout, Christopher B. Granger, Paul W. Armstrong
- Increase in tissue and circulating pentraxin3 levels in patients with aortic valve stenosis
- Yoshiro Naito, Takeshi Tsujino, Hirokuni Akahori, Mitsumasa Ohyanagi, Masataka Mitsuno, Yuji Miyamoto, Hiroyuki Hao, Seiichi Hirota, Tohru Masuyama
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?